Q2 2025 Financial Performance - Revenue reached $1,109 million, an 11% reported growth and 9% organic growth[1] - Operating profit was $373 million, representing 34% of revenue[1] - Diluted earnings per share (EPS) grew by 49% to $3.63, with a comparable growth of 17%[1] - CAG (Companion Animal Group) Diagnostics Recurring revenue reported growth of 9% and organic growth of 7%, with a 730 bps reported and 130 bps comparable year-over-year change in basis points[1] Segment Revenue Growth - CAG revenue was $1,022 million, with 11% reported growth and 10% organic growth[1] - Water revenue reached $51 million, showing 9% reported growth and 8% organic growth[1] - LPD (Livestock, Poultry and Dairy) revenue was $32 million, with 5% reported growth and 3% organic growth[1] 2025 Financial Outlook - Revenue is projected to be between $4,205 million and $4,280 million, representing 7.7% to 9.7% reported growth and 7.0% to 9.0% organic growth[6,7] - Operating margin is expected to be 31.3% to 31.6%, with a reported margin expansion of 240 to 270 bps and a comparable margin expansion of 50 to 80 bps[6,7] - EPS is forecasted to be $12.40 to $12.76, indicating 16% to 20% reported growth and 9% to 13% comparable growth[6,7] U S Companion Animal Practice Growth (As of June 30, 2025) - U S companion animal practices experienced a 6.1% year-over-year growth in total practice revenue[9] - Total visits to U S companion animal practices decreased by 3.4% year-over-year[9] - Clinical visits decreased by 2.5%, while non-wellness visits decreased by 2.7% year-over-year[9] - Diagnostic revenue per clinical visit increased by 4.5% year-over-year[14]

Q1 2025 Financial Performance - Revenue reached $998 million, with a reported growth of +4% and organic growth of +5%[1] - Operating profit was $317 million, representing 31.7% of revenue[1] - Diluted earnings per share (EPS) grew by +5% to $2.96[1] Segment Performance - CAG (Companion Animal Group) revenue totaled $920 million, with reported growth of +3% and organic growth of +4%[1] - Water revenue was $45 million, showing reported growth of +5% and organic growth of +7%[1] - LPD (Livestock, Poultry and Dairy) revenue reached $29 million, with reported growth of +1% and organic growth of +4%[1] - Within CAG Diagnostics Recurring revenue, IDEXX VetLab® Consumables grew by +9% reported and +10% organically, reaching $345 million[1] - Reference Laboratory Dx and Consulting Services revenue was $344 million, with 0% reported growth and +1% organic growth[1] Premium Instrument Placements - Catalyst® placements totaled 1,469 worldwide, with 530 in the U S and 939 internationally[1] - Premium Hematology placements reached 1,597 worldwide, with 441 in the U S and 1,156 internationally[1] - SediVue® Dx placements were 795 worldwide, with 288 in the U S and 507 internationally[1] 2025 Outlook - Revenue is projected to be between $4,095 million and $4,210 million, with reported growth of 5 0% to 8 0% and organic growth of 6 0% to 9 0%[6] - EPS is expected to be between $11 93 and $12 43, with reported growth of 12% to 17%[6] - Capital expenditures are estimated at approximately $160 million[6] U.S. Companion Animal Practice Growth - As of March 31, 2025, U S companion animal practice revenue showed a year-over-year growth of +2 3% per practice[9] - Total visits experienced a year-over-year decline of -2 6% per practice[9] - Clinical visits decreased by -2 3%, while non-wellness visits showed a decline of -2 6%[9]